Clinical Trials

Multiple Myeloma, Recurrence

NCT05519085 2026-03-11

SUCCESSOR-1

Phase 3 Recruiting

810 enrolled

Multiple Myeloma, Recurrence

NCT07138209 2026-02-27

A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma

Phase 3 Recruiting

228 enrolled

Phase 2 Active not recruiting

Multiple Myeloma, Recurrence

NCT02718833 2026-01-22

A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma

52 enrolled

Phase 3 Active not recruiting

Multiple Myeloma, Recurrence

NCT05455320 2026-01-16

MonumenTAL-3

864 enrolled

Multiple Myeloma, Recurrence

NCT05922501 2026-01-14

ISABELA

Phase 2 Recruiting

50 enrolled

Multiple Myeloma, Recurrence

NCT07312188 2025-12-31

A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Phase 2 Recruiting

90 enrolled

Multiple Myeloma, Recurrence

NCT02343042 2025-12-22

STOMP

Phase 1/2 Recruiting

300 enrolled

Phase 2 Active not recruiting

Multiple Myeloma, Recurrence

NCT05911321 2025-10-20

Isa-Pom-Dex in Elderly/Frail Subjects With RRMM

6 enrolled

Multiple Myeloma, Recurrence

NCT04176718 2025-10-07

Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM

Phase 2 Recruiting

43 enrolled

Multiple Myeloma, Recurrence

NCT04191616 2025-09-04

SELECT

54 enrolled 17 charts

Multiple Myeloma, Recurrence

NCT06163040 2025-07-31

A Study to Evaluate the Safety of Empliciti® (Elotuzumab) When Treating Patients With Multiple Myeloma in Taiwan

Completed

7 enrolled

Phase 3 Active not recruiting

Multiple Myeloma, Recurrence

NCT03539744 2025-06-19

A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.

265 enrolled

Multiple Myeloma, Neoplasms, Recurrence

NCT03288974 2025-04-15

Pomalyst PMS

Completed

397 enrolled

Multiple Myeloma, Recurrence

NCT04150965 2025-02-14

Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT

Phase 1/2 Terminated

14 enrolled

Phase 2 Active not recruiting

Multiple Myeloma, Recurrence

NCT02406222 2024-12-05

MUKseven

124 enrolled

Multiple Myeloma, Recurrence

NCT02616640 2024-09-19

A Study to Determine Dose and Regimen of Durvalumab as Monotherapy or in Combination With Pomalidomide With or Without Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma

114 enrolled

Multiple Myeloma, Recurrence

NCT02294357 2023-11-01

Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib

Phase 2 Terminated

45 enrolled

Multiple Myeloma, Recurrence

NCT02206425 2023-10-31

Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients

Phase 1/2 Completed

45 enrolled

Multiple Myeloma, Recurrence

NCT04895410 2023-03-06

Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Lemzoparlimab With or Without Oral/IV Dexamethasone and in Combination With Oral/IV/Subcutaneous Anti-Myeloma Regimens in Adult Participants With Multiple Myeloma

Phase 1 Terminated

8 enrolled

Multiple Myeloma, Neoplasms, Recurrence

NCT03439280 2023-02-24

A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Participants With Relapsed/Refractory (r/r) Multiple Myeloma (MM)

Phase 1/2 Completed

50 enrolled 26 charts

Phase 3 Active not recruiting

Multiple Myeloma, Recurrence

NCT03651128 2022-12-15

KarMMa-3

381 enrolled

Multiple Myeloma, Recurrence

NCT05236621 2022-02-11

A Study of the Efficacy and Safety of Pomalidomide Capsules Combined With Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma

Phase 3 Unknown

85 enrolled

Multiple Myeloma, Recurrence

NCT01712789 2022-01-10

STRATUS

Phase 3 Completed

682 enrolled 23 charts

Multiple Myeloma, Recurrence

NCT01177735 2021-04-22

Pomalidomide in Gene Expression Profiling (GEP)-Defined High-risk Multiple Myeloma

71 enrolled 7 charts

Multiple Myeloma, Recurrence

NCT04762745 2021-02-21

The Efficacy and Safety of Pomalidomide and Bendamustine With Dexamethasone in Relapsed or Refractory Multiple Myeloma

Phase 1/2 Unknown

56 enrolled

Multiple Myeloma, Recurrence

NCT01497093 2020-04-07

Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

34 enrolled

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT02189343 2019-11-21

Phase 1b Study Evaluating ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed-and-Refractory Multiple Myeloma

16 enrolled

Disease, Multiple Myeloma, Recurrence, Disease Progression

NCT01324947 2019-11-19

Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple Myeloma

Phase 3 Completed

74 enrolled 17 charts

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT01632826 2019-11-12

PEXIUS

Approved for marketing

Multiple Myeloma, Recurrence

NCT02289222 2019-11-05

1454GCC: Anti-PD-1 (MK-3475) and IMiD (Pomalidomide) Combination Immunotherapy in Relapsed/Refractory Multiple Myeloma

Phase 1/2 Terminated

48 enrolled 10 charts

Multiple Myeloma, Recurrence

NCT02176213 2019-06-18

Study of Pomalidomide, Cyclophosphamide, Dexamethasone in Relapsed/Refractory Multiple Myeloma

35 enrolled

Multiple Myeloma, Recurrence

NCT03601624 2018-11-14

MM-POM-2018

Phase 2 Unknown

18 enrolled

Multiple Myeloma, Recurrence, Disease Progression

NCT02103335 2017-11-22

Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Relapsed and Refractory Multiple Myeloma

38 enrolled

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT02046915 2017-10-30

PERSPECTIVE

60 enrolled

Multiple Myeloma, Recurrence

NCT01432600 2017-05-23

Pomalidomide in Combination With High Dose Dexamethasone and Oral Cyclophosphamide

Phase 1/2 Completed

80 enrolled 12 charts

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT02578121 2017-01-23

UARK 2015-03 A Phase II Trial of a Novel Proteasome/IMiD Combination

Phase 2 Withdrawn

Multiple Myeloma, Recurrence

NCT02011113 2016-11-01

Japanese Phase 2 Study to Evaluate the Efficacy and Safety of Pomalidomide in Subjects With Relapsed and Refractory Multiple Myeloma

36 enrolled 18 charts

Multiple Myeloma, Recurrence

NCT01889420 2015-07-31

Phase I Trial of Everolimus, Pomalidomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma

Phase 1 Terminated

1 enrolled 3 charts